Thrivent Financial for Lutherans Lowers Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Thrivent Financial for Lutherans lowered its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 44.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,619 shares of the specialty pharmaceutical company’s stock after selling 11,574 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Jazz Pharmaceuticals were worth $1,629,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. CWA Asset Management Group LLC purchased a new position in Jazz Pharmaceuticals during the third quarter worth approximately $3,197,000. Swedbank AB acquired a new position in Jazz Pharmaceuticals in the second quarter valued at $106,936,000. Philip James Wealth Mangement LLC purchased a new stake in Jazz Pharmaceuticals during the third quarter valued at about $830,000. Victory Capital Management Inc. grew its position in Jazz Pharmaceuticals by 42.7% during the second quarter. Victory Capital Management Inc. now owns 205,492 shares of the specialty pharmaceutical company’s stock valued at $21,932,000 after acquiring an additional 61,458 shares during the period. Finally, Thompson Siegel & Walmsley LLC increased its stake in Jazz Pharmaceuticals by 30.6% during the second quarter. Thompson Siegel & Walmsley LLC now owns 721,530 shares of the specialty pharmaceutical company’s stock worth $77,009,000 after acquiring an additional 168,957 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the transaction, the senior vice president now owns 14,531 shares of the company’s stock, valued at $1,573,707.30. This trade represents a 8.85 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the transaction, the executive vice president now owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 6,110 shares of company stock valued at $720,160. 4.20% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on JAZZ shares. TD Cowen reduced their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. JPMorgan Chase & Co. lifted their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research report on Monday, August 19th. Cantor Fitzgerald reissued an “overweight” rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. Piper Sandler reissued an “overweight” rating and issued a $163.00 target price (down previously from $166.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. Finally, Robert W. Baird upped their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. Three research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $175.33.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $121.59 on Friday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $134.17. The business has a 50 day moving average price of $114.87 and a two-hundred day moving average price of $111.12. The firm has a market cap of $7.35 billion, a PE ratio of 17.13, a price-to-earnings-growth ratio of 1.03 and a beta of 0.57.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.